PA8594401A1 - Acidos carboxilicos de heteroarilo condensado como agonista del ppar - Google Patents

Acidos carboxilicos de heteroarilo condensado como agonista del ppar

Info

Publication number
PA8594401A1
PA8594401A1 PA20048594401A PA8594401A PA8594401A1 PA 8594401 A1 PA8594401 A1 PA 8594401A1 PA 20048594401 A PA20048594401 A PA 20048594401A PA 8594401 A PA8594401 A PA 8594401A PA 8594401 A1 PA8594401 A1 PA 8594401A1
Authority
PA
Panama
Prior art keywords
condensed
heteroarilo
ppar agonist
carboxilic acids
carboxilic
Prior art date
Application number
PA20048594401A
Other languages
English (en)
Inventor
Wei-Guo Su
Donald James Skalitzky
Luke Raymond Zehnder
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8594401A1 publication Critical patent/PA8594401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

ACIDOS CARBOXILICOS DE HETEROARILO CONDENSADO DE FORMULA (1): EN LA QUE R1, AR, A, Y, HET, Q Y T SON COMO SE HAN DEFINIDO EN LA MEMORIA DESCRIPTIVA; COMPOSICIONES FARMACEUTICAS QUE CONTIENEN CANTIDADES EFICACES DE DICHOS COMPUESTOS O SUS SALES SON UTILES PARA TRATAR TRASTORNOS RELATIVOS A PPAR, TALES COMO DIABETES, DISLIPIDEMIA, OBESIDAD Y TRASTORNOS INFLAMATORIOS.
PA20048594401A 2003-02-21 2004-01-22 Acidos carboxilicos de heteroarilo condensado como agonista del ppar PA8594401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44893103P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
PA8594401A1 true PA8594401A1 (es) 2004-09-16

Family

ID=32908672

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048594401A PA8594401A1 (es) 2003-02-21 2004-01-22 Acidos carboxilicos de heteroarilo condensado como agonista del ppar

Country Status (14)

Country Link
US (1) US20040209929A1 (es)
EP (1) EP1597257A1 (es)
JP (1) JP2006518366A (es)
AR (1) AR044498A1 (es)
BR (1) BRPI0407735A (es)
CA (1) CA2516475A1 (es)
GT (1) GT200400019A (es)
MX (1) MXPA05008922A (es)
NL (1) NL1025542C2 (es)
PA (1) PA8594401A1 (es)
PE (1) PE20050223A1 (es)
TW (1) TW200424201A (es)
UY (1) UY28200A1 (es)
WO (1) WO2004074284A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070083333A1 (en) * 2003-11-17 2007-04-12 Vitiello Maria A Modeling of systemic inflammatory response to infection
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
EP1786782B1 (en) * 2004-08-12 2010-03-31 Amgen Inc. Bisaryl-sulfonamides
BRPI0515168A (pt) 2004-09-11 2008-07-08 Sanofi Aventis Deutschland 7-azaindóis, processos para sua preparação e seu uso como fármacos
WO2006053342A2 (en) * 2004-11-12 2006-05-18 Osi Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
MX2011004125A (es) * 2008-10-21 2011-05-19 Metabolex Inc Agonistas del receptor gpr120 de arilo y usos de los mismos.
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
JP6369951B2 (ja) * 2015-08-26 2018-08-08 三井農林株式会社 ジペプチジルペプチダーゼ−ｉｖ阻害剤
WO2017121308A1 (en) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Fused pyridine compounds, compositions and methods of use
WO2018202039A1 (zh) * 2017-05-03 2018-11-08 成都海创药业有限公司 杂环化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
DE69530501D1 (de) * 1994-10-20 2003-05-28 Nippon Chemiphar Co Chinolinderivat
YU50302A (sh) * 1999-12-03 2006-01-16 Kyoto Pharmaceutical Industries Ltd. Nova heterociklična jedinjenja, njihove soli i njihova primena u medicini
EP1405848B1 (en) * 2001-06-18 2008-05-07 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
DE60210784T2 (de) * 2001-08-29 2006-11-02 Warner-Lambert Co. Llc Orale antidiabetische wirkstoffe
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents

Also Published As

Publication number Publication date
TW200424201A (en) 2004-11-16
MXPA05008922A (es) 2005-10-05
JP2006518366A (ja) 2006-08-10
BRPI0407735A (pt) 2006-02-14
UY28200A1 (es) 2004-09-30
US20040209929A1 (en) 2004-10-21
GT200400019A (es) 2004-09-21
WO2004074284A1 (en) 2004-09-02
CA2516475A1 (en) 2004-09-02
EP1597257A1 (en) 2005-11-23
PE20050223A1 (es) 2005-03-22
NL1025542C2 (nl) 2005-10-11
AR044498A1 (es) 2005-09-14
NL1025542A1 (nl) 2004-08-24

Similar Documents

Publication Publication Date Title
PA8600201A1 (es) Acidos carboxilicos alfa sustituidos como moduladores ppar
EA202091893A1 (ru) Новые кристаллические формы
DK2150530T3 (da) Substituerede sulfonamid-derivater
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA201070423A1 (ru) Диарильные соединения оксадиазолов
EA201070422A1 (ru) Производные оксадиазола
NO20083153L (no) Kjemiske forbindelser
AR058807A1 (es) 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
CL2007002867A1 (es) Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA200900403A1 (ru) Соединения, которые модулируют рецептор св2
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
UY30812A1 (es) Sulfonatos { 2-amino-4-[r-fenil]-1-metil-5-oxo-4,5-dihidro-1 h-imidazol-4-il}fenil sustituidos, composiciones conteniéndolos y aplicaciones
EA201070039A1 (ru) Спироциклы в качестве ингибиторов 11-бета гидроксилстероиддегидрогеназы типа 1
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
EA201171211A1 (ru) Производные оксадиазола
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
GB0524814D0 (en) Compounds
PA8594401A1 (es) Acidos carboxilicos de heteroarilo condensado como agonista del ppar
CY1113178T1 (el) Σταθεροποιημενες αμορφες μορφες της μεσυλικης ιματινιβης